Kekst & Co is handling Avista Capital Markets private equity firm's merger of a "blank check company" with Organogenesis Inc. advanced wound care and sports medicine operation.

ACM has agreed to invest $92M in Canton, MA-based Organogenesis, which is expected to trade on the NASDAQ with an enterprise value in the $675M range when the deal closes by the end of the year.

Organogenesis has more than 600 employees involved in the development, manufacture and commercialization of products in the regenerative medicine sector.

Tom Dean, CEO of Avista Healthcare Public Acquisition Corp., said Organogenesis is "well-positioned to benefit from secular tailwinds driving the advance would care, surgical and sports medicine sectors."

Kekst's Daniel Yunger reps Avista and AHPAC.